In this task, you're given a paragraph from the research paper and your task is to generate a suitable title for the research paper based on the given paper. Under 100 words is a good title length.

[EX Q]: IFITM3 restricts cellular infection by multiple important viral pathogens, and is particularly critical for the innate immune response against influenza virus. Expression of IFITM3 expands acidic endolysosomal compartments and prevents fusion of endocytosed viruses, leading to their degradation. This small, 133 amino acid, antiviral protein is controlled by at least four distinct post-translational modifications. Positive regulation of IFITM3 antiviral activity is provided by Spalmitoylation, while negative regulatory mechanisms include lysine ubiquitination, lysine methylation and tyrosine phosphorylation. Herein, we describe specific insights into IFITM3 trafficking and activity that were provided by studies of IFITM3 post-translational modifications, and discuss evidence suggesting that IFITM3 adopts multiple membrane topologies involving at least one intramembrane domain in its antivirally active conformation.
[EX A]: Regulation of the trafficking and antiviral activity of IFITM3 by post-translational modifications

[EX Q]: Objective: The aim of this study was to further clarify clinical characteristics and predict mortality risk among patients with viral pneumonia. Methods: A total of 528 patients with viral pneumonia at RuiJin hospital in Shanghai from May 2015 to May 2019 were recruited. Multiplex real-time RT-PCR was used to detect respiratory viruses. Demographic information, comorbidities, routine laboratory examinations, immunological indexes, etiological detections, radiological images and treatment were collected on admission. Results: 76 (14.4%) patients died within 90 days in hospital. A predictive MuLBSTA score was calculated on the basis of a multivariate logistic regression model in order to predict mortality with a weighted score that included multilobular infiltrates (OR = 5.20, 95% CI 1.41-12.52, p = 0.010; 5 points), lymphocyte ≤ 0.8 * 10 9 /L (OR = 4.53, 95% CI 2.55-8.05, p < 0.001; 4 points), bacterial coinfection (OR = 3.71, 95% CI 2.11-6.51, p < 0.001; 4 points), acute-smoker (OR = 3.19, 95% CI 1.34-6.26, p = 0.001; 3 points), quit-smoker (OR = 2.18, 95% CI 0.99-4.82, p = 0.054; 2 points), hypertension (OR = 2.39, 95% CI 1.55-4.26, p = 0.003; 2 points) and age ≥60 years (OR = 2.14, 95% CI 1.04-4.39, p = 0.038; 2 points). 12 points was used as a cut-off value for mortality risk stratification. This model showed sensitivity of 0.776, specificity of 0.778 and a better predictive ability than CURB-65 (AUROC = 0.773 vs. 0.717, p < 0.001). Conclusion: Here, we designed an easy-to-use clinically predictive tool for assessing 90-day mortality risk of viral pneumonia. It can accurately stratify hospitalized patients with viral pneumonia into relevant risk categories and could provide guidance to make further clinical decisions.
[EX A]: Citation: Clinical Features Predicting Mortality Risk in Patients With Viral Pneumonia: The MuLBSTA Score

[EX Q]: At least 20-50% of all ICU admissions occur in patients older than 65 years of age, and geriatric patients account for almost 60% of all ICU days. Unfortunately, many older patients' fi nal days are spent in the ICU; 40% of Medicare patients who die are admitted to an ICU during their terminal illness, accounting for 25% of all Medicare expenditures. Additionally, of those who survive, many are discharged to a subacute facility with persistent organ failure where they will eventually die. Furthermore, those discharged to a subacute care facility have a higher mortality rate compared to those discharged home (31 vs. 17%). The decision to admit an elderly patient to an ICU should be based not only on their comorbidities, acuity of illness, and prehospital functional status, including quality of life, but also on their preference for the use of life-sustaining treatments if it is known. The underlying disease process is not altered despite the use of invasive procedures in terminally ill patients, and potential harm or discomfort can occur if invasive procedures are used inappropriately. To avoid such unintended consequences and enhance optimal end-of-life decision making, healthcare providers need to identify, explain, and negotiate consensus therapeutic goals. In 2005, spending by Medicare for those older than 65 years totaled $342 billion, representing 17.1% of the total of $2 trillion spent nationwide for health care. Intensive care consumes 4% of national healthcare expenditures. During the last 6 months of their lives, 11% of Medicare recipients spend 8 or more days in the ICU; various studies documenting ICU occupancy by those older than 65 years old note that this ranges from one quarter to one half of the available beds. These statistics alone show the profound fi nancial burden that must be borne to provide a medically sound and appropriate depth of care, a signi fi cant portion of which will be provided in the ICU.
[EX A]:
The Elderly Patient and the Intensive Care Unit